Nasdaq grants adamis pharmaceuticals' request for extension to comply with continued listing requirements

San diego, feb. 22, 2023 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that the nasdaq hearings panel (the “panel”) has granted the company's request for continued listing on nasdaq, pursuant to an extension through june 26, 2023 to evidence compliance with the $1.00 bid price requirement and its continued compliance with all other applicable criteria for continued listing on the nasdaq capital market (the “compliance period”).
ADMP Ratings Summary
ADMP Quant Ranking